Michael Amoroso has been Chairman of Abeona's Board since October 15, 2021 and a director since March 19, 2021. Since October 2021 he has served as President and Chief Executive Officer of Precision BioSciences, Inc. (Nasdaq: DTIL). He previously served as Abeona's President and Chief Executive Officer from March to October 2021, having joined in July 2020 as Chief Commercial Officer and been promoted to Chief Operating Officer in November 2020. From 2018 to 2020 he was Senior Vice President and Head of Worldwide Commercial Operations for Cell Therapy at Kite Pharma (a Gilead subsidiary), where he helped bring YESCARTA to market, and earlier held senior executive positions at Eisai Inc. and Celgene Corporation. He earned an Executive MBA from NYU's Stern School of Business and a B.A. in Biological Sciences, summa cum laude, from Rider University.